Latest News
Result of General Meeting
06 May 2020
Tiziana Life Sciences plc
("Tiziana" or the "Company")
At the General Meeting of the Company held at 11.00 a.m. on 6 May 2020, the resolutions to seek additional authorities to issue shares, to disapply pre-emption rights, replacement of option grants and adoption...
TR-1: Standard form for notification of major holdings
06 May 2020
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i |
||||||
| ... |
Total Voting Rights
01 May 2020
For the purposes of the Disclosure Guidance and Transparency Rules, the Company is required to notify the market of the following:
During the month of April 2020, 906,905 Ordinary Shares were issued to support the allotment and issue of sales of...
Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses
27 April 2020
Combination of nanoparticle-Actinomycin D acting as an anti-viral treatment, with an anti-inflammatory agent may present a potential therapeutic option for COVID-19 patients.
New York/London - April 27, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a...
Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia
24 April 2020
Nanoparticle Actinomycin formulation minimizes toxicity and enhances tolerability by slow release of drug to control Cmax in blood
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
New York/London - April 24, 2020 – Tiziana Life...
Issue of Equity and Resulting Total Voting Rights. Update on AIM cancellation and migration to Nasdaq.
24 April 2020
London, New York, 24 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease...